Fifty-seven year old Dr. Clay Siegall
Fifty-seven year old, Dr. Clay Siegall, Ph.D. founded Seattle Genetics incorporation in 1998. He acquired a bachelor of science in Zoology from the University of Maryland and a postgraduate in Genetics from George Washington University. He has spent about years of his life in cancer research and creation of pharmaceuticals.
He is currently the President, Chief Executive Officer and Chairman of the board at Seattle Genetics. On top of that, he is Director at Alder Biopharmaceuticals Incorporation and Ultragenyx Pharmaceutical Incorporation. Previously he worked at Bristol Squibb Pharmaceutical Research Institute as the Director and the National Institute of health.
Seattle Genetics was as the product of Clay’s passion for active, extensive research, innovation, the creation of new drugs and aiding patients. Under his leadership, the company has been quite successful in coming up with an antibody-drug conjugate (ADC), which received Food and Drug Association approval in 2011 and is now used worldwide as a therapy for cancer.
Dr. Clay Siegall has received several accolades in his career. In 2012 he received the Pacific Northwest Ernst and Young Entrepreneur of the year award. The following year, University of Maryland recognized him as Alumnus of the year in Natural Sciences, Mathematics and Computer. He has also authored seventy plus papers in cancer and has received over fifteen recognitions by the government for his groundbreaking work in cancer treatment.
During a recent interview with Ideasmensch, he revealed that his inspiration to start Seattle Genetics was watching his father succumb due to cancer when he was only 24. He had watched him suffer in pain for several years with little the doctors could do to help him due to the few resources to fight the disease that was available back then.
He aims to make better what is available and to find a cure for cancer ultimately. He advised people always to be hungry for knowledge, still yearn to learn and ensure they meet knowledgeable persons. Fostering partnerships with other companies in the industry such as Takeda Pharmaceutical is what has helped the company grow as he revealed during the interview.